Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
C4 TherapeuticsCCCC +2.50%49 3-Year EBITDA Growth Rate is 21.40% as of Jun. 2026, which is 1238% above its 10-year median of 1.60. GuruFocus rates CCCC with a GF Score™ of 49/100 and a GF Value™ of $2.05 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,130 Biotechnology companies, C4 Therapeutics ranks better than 57.88% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 21.40% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 19.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 8 years, the highest 3-Year average EBITDA Per Share Growth Rate of C4 Therapeutics was 23.00% per year. The lowest was -19.50% per year. And the median was 1.60% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
C4 Therapeutics 3-Year EBITDA Growth Rate Related Terms
CCCC vs CMPX, AVIR, STRO: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, C4 Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
C4 Therapeutics 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, C4 Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where C4 Therapeutics's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 21.40% mean?
C4 Therapeutics (CCCC) has a 3-Year EBITDA Growth Rate of 21.40% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for C4 Therapeutics and its competitors. This is 1238% above median its historical median of 1.60. According to the industry distribution chart, C4 Therapeutics ranks #476 out of 1130 companies in the Biotechnology industry, placing it in the top 42.1%.
Is C4 Therapeutics' 3-Year EBITDA Growth Rate too high?
C4 Therapeutics' current 3-Year EBITDA Growth Rate of 21.40% is 1238% above median its 10-year median of 1.60. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.85. C4 Therapeutics' value of 21.40% is 44.1% above this industry median. Based on the distribution chart, C4 Therapeutics ranks #476 out of 1130 companies in the Biotechnology industry, which is above the industry midpoint. Overall, C4 Therapeutics has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does C4 Therapeutics' 3-Year EBITDA Growth Rate compare to CMPX and AVIR?
According to the Biotechnology industry distribution chart, C4 Therapeutics ranks #476 out of 1130 companies for 3-Year EBITDA Growth Rate. This puts C4 Therapeutics in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.85. C4 Therapeutics' value of 21.40% is 44.1% above this benchmark. While the company's 10-year median is 1.60 vs. the industry median of 14.85, C4 Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.85, based on 1,130 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. C4 Therapeutics's current 3-Year EBITDA Growth Rate of 21.40% is 44.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for C4 Therapeutics and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. C4 Therapeutics's current 3-Year EBITDA Growth Rate is 21.40%, which is 1238% above median its own 10-year median of 1.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is C4 Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, C4 Therapeutics (CCCC) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.05, compared to a current price of $4.12 — trading 100.7% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 21.40%, which is 1238% above median its 10-year median of 1.60 and 44.1% above the Biotechnology industry median of 14.85. C4 Therapeutics' overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For C4 Therapeutics (CCCC), the current 3-Year EBITDA Growth Rate is 21.40% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is C4 Therapeutics (CCCC) Overvalued in 2026?
Based on GuruFocus' analysis, C4 Therapeutics stock appears to be overvalued.
The current stock price of $4.12 is trading 100.7% above its estimated GF Value™ of $2.05.
GuruFocus considers C4 Therapeutics to be Significantly Overvalued.
Key valuation signals for CCCC:
3-Year EBITDA Growth Rate: 21.40% (1238% above median its 10-year median of 1.60)
GF Value™: $2.05 vs. price of $4.12 (100.7% above fair value)
Industry Position: 44.1% above the Biotechnology median (#476 of 1130)
No single metric tells the full story. See the CCCC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.
49GF Score
Get the complete analysis for CCCC
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CCCC has been successfully added to your 
